[HTML][HTML] Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer
MK McGrath, A Abolhassani, L Guy… - Frontiers in …, 2024 - frontiersin.org
Estrogen receptor positive (ER+) breast cancer is the most common breast cancer
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …
Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer
M McGrath, A Abolhassani, L Guy… - Frontiers in …, 2024 - europepmc.org
Estrogen receptor positive (ER+) breast cancer is the most common breast cancer
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …
[HTML][HTML] Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer
MK McGrath, A Abolhassani, L Guy… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Estrogen receptor positive (ER+) breast cancer is the most common breast cancer
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …
Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer
MK McGrath, A Abolhassani, L Guy… - Frontiers in …, 2024 - pubmed.ncbi.nlm.nih.gov
Estrogen receptor positive (ER+) breast cancer is the most common breast cancer
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …
Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer
MK McGrath, A Abolhassani, L Guy… - Frontiers in …, 2024 - augusta.elsevierpure.com
Estrogen receptor positive (ER+) breast cancer is the most common breast cancer
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …
[PDF][PDF] Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer
MK McGrath, A Abolhassani, L Guy, AM Elshazly… - 2024 - researchgate.net
It is estimated that in 2023, in the United States over 275,000 cases of invasive breast
cancer will be diagnosed in women and over 2,500 cases in men (1). Of these breast …
cancer will be diagnosed in women and over 2,500 cases in men (1). Of these breast …
Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer.
MK McGrath, A Abolhassani, L Guy… - Frontiers in …, 2024 - europepmc.org
Estrogen receptor positive (ER+) breast cancer is the most common breast cancer
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …